Grants for Special district governments - Food and Nutrition

This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

The Green Transportation Capital Grant Program, administered by the Washington State Department of Transportation, aims to fund cost-effective capital projects for transit authorities. Its core mission is to reduce the carbon intensity of Washington's transportation system, aligning with broader climate action efforts supported by the state's Climate Commitment Act (CCA). The CCA's strategic priority is to decrease climate pollution, create jobs, and enhance public health, making this grant a direct mechanism to achieve these goals by investing in sustainable transportation solutions. The primary beneficiaries of this program are transit agencies within Washington state, including various city, county, metropolitan, public, unincorporated, regional, and special purpose district transit systems. The impact goals are centered on transforming public transportation infrastructure to be more environmentally friendly. This includes the electrification of transit vehicle fleets and the development of necessary supporting infrastructure, such as charging and fueling stations, and associated electrical system upgrades. The program prioritizes capital projects that directly contribute to fleet electrification and the transition to zero-emission transportation. Eligible projects encompass the acquisition of battery and fuel cell-operated electric vehicles, modification of facilities for electrification or hydrogen refueling, and the construction of new facilities that primarily support electrified fleets. Additionally, it covers essential upgrades to electrical transmission and distribution systems, in-house staff managing capital construction, and property rights acquisition for these projects. The expected outcomes and measurable results include a significant reduction in carbon emissions from the Washington transportation sector, directly contributing to the state's climate goals. Historically, the program has awarded between $12 million and $50 million per biennium, indicating a substantial investment in achieving these outcomes. The project period for most applications is two years (July 1, 2025 – June 30, 2027), with construction projects potentially extending to four years, allowing for tangible progress in transitioning to green transportation.

Not Available

This funding opportunity provides financial support for new researchers from diverse backgrounds to conduct small-scale health-related studies, helping them advance towards independent research careers.

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P and F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

The Chautauqua County Tourism Product Development Grant Program, with a deadline of 10/01/2024, offers $10,000 to $100,000 for projects that enhance tourism and recreation opportunities, increase visibility, and promote overnight stays in the county, with a focus on event development, marketing, and attraction enhancement.

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants. The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.

This funding opportunity supports researchers and organizations in improving and sustaining software tools for biomedical and health-related research by adopting best practices and enhancing collaboration within the scientific community.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit grant applications from neutral, independent institutions and/or organizations to support meetings (e.g., conferences, workgroups, roundtables) that convene a broad range of multiple stakeholders, including those with relevant expertise, to explore, research, and address issues related to medical products, policy, and surveillance methods and systems. Support includes, but is not limited to the design, planning, execution, synthesis, summary, and communication of findings from these forums to a broad range of organizations and individuals.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R01 grant mechanism, while RFA-MH-25-186 uses the R21 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.

This grant provides funding to support early-career researchers from diverse backgrounds in developing independent careers focused on Alzheimer's disease and related dementias through mentored training and research opportunities.

This program provides financial support to food retailers in underserved communities to improve access to healthy food options for low- and moderate-income populations.

This grant provides financial support to charitable organizations serving Lenoir County, North Carolina, focusing on enhancing community quality of life through various local initiatives.

This funding opportunity provides $1 million to various organizations to develop and implement strategies for effectively sharing clinical practice guidelines, particularly in underserved communities, to improve healthcare quality and equity.

This funding opportunity supports a central hub for collaboration between the FDA and the generic drug industry, focusing on research and development of complex generics to improve access to safe and effective medications.